ClinicalTrials.gg
CompletedNCT03486314Updated Apr 18, 2022Results posted

A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors

A Phase 1 interventional study of Pevonedistat and Rifampin in Advanced Solid Neoplasm, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-18.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the effect of multiple-dose administration of rifampin on the single dose PK of pevonedistat in adult participants with advanced solid tumors.

Read the detailed description

The study will enroll approximately 20 participants. The study will be conducted in two Parts: Part A and optional Part B. Part A will have a drug-drug interaction (DDI) assessment. In Part A, participants will be assigned to:

  • Pevonedistat 50 mg/m\^2 + Rifampin

Eligible participants from Part A will continue treatment in optional Part B with pevonedistat in combination with SoC chemotherapy, docetaxel or carboplatin plus paclitaxel. The investigator will decide which SoC combination partner a participant will receive.

  • Pevonedistat 25 mg/m\^2 + Docetaxel
  • Pevonedistat 20 mg/m\^2 + Carboplatin + Paclitaxel

This multi-center trial will be conducted in the United States. The overall time to participate in this study is 18 months. Participants will make a final visit to the clinic 30 days after receiving their last dose of study drug or before the start of subsequent therapy.

02

Conditions studied

  • Advanced Solid Neoplasm

Keywords

  • Drug therapy
03

In context

Lead sponsor

Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.

Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.

First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult participants who have a or cytologically confirmed or locally advanced solid tumor that is appropriate for treatment with either docetaxel or carboplatin + paclitaxel in Part B of this study, or have progressed despite standard therapy, or for whom conventional therapy is not considered effective.
  2. (ECOG) performance status of 0 to 1.
  3. Expected survival of at least 3 months from the date of enrollment in the study.
  4. Recovered (that is, less than or equal to (\<=) Grade 1 toxicity) from the effects of prior antineoplastic therapy.
  5. Adequate organ functions (kidney, liver, cardiac, bone marrow).
  6. Suitable venous access for the study-required blood sampling (including PK sampling).

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with radiation therapy involving greater than or equal to (>=) 25% of the hematopoietically active bone marrow.
  2. Life-threatening illness or serious (acute or chronic) medical or psychiatric illness unrelated to cancer.
  3. Active, uncontrolled infection or severe infectious disease.
  4. Known (HIV) seropositive or known or infection.
  5. With significant heart or pulmonary disease.
  6. Requiring chronic treatment with breast cancer resistance protein (BCRP) inhibitors.

Criteria for Continuation into Optional Part B:

To be eligible for Part B, participants must have completed Part A and be reassessed to determine if they meet the continuation criteria for Part B.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg

    Pevonedistat 50 milligram per square meter (mg/m\^2), intravenous infusion, once on Day 1 and 10 along with rifampin 600 milligram (mg), capsule, orally, once daily from Day 3 up to Day 11 in Part A. After completion of Part A, participants had opportunity to continue into optional Part B.

    Drug: Pevonedistat · Drug: Rifampin

  • Experimental
    Part B: Pevonedistat

    Pevonedistat 25 mg/m\^2 intravenously in combination with docetaxel 75 mg/m\^2 or at 20 mg/m\^2 in combination with carboplatin +paclitaxel 175 mg/m\^2; pevonedistat was given in combination on Day 1 and as a single agent on Days 3 and 5 of each 21-day cycle. Participants were treated for up to 12 cycles or symptomatic deterioration or PD, treatment was discontinued for another reason, or until the study is stopped in Part B. The choice of combination partner (docetaxel or carboplatin + paclitaxel) was based on investigator discretion. If the sponsor and investigator determine that a participant would derive clinical benefit from continued treatment, the participant may remain on the current combination therapy or receive pevonedistat as a single agent beyond 12 cycles.

    Drug: Pevonedistat · Drug: Docetaxel · Drug: Carboplatin · Drug: Paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Part A: Ratio of Maximum Observed Plasma Concentration (Cmax) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)

    The Least square (LS) means ratio of Day 10 over Day 1 were calculated from a mixed-model analysis of variance model.

    Time frame: Days 1 and 10 pre-dose and at multiple time points (up to 48 hours) post-dose

  2. Part A: Ratio of Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)

    The LS means ratio of Day 10 over Day 1 were calculated from a mixed-model analysis of variance model.

    Time frame: Days 1 and 10 pre-dose and at multiple time points (up to 48 hours) post-dose

  3. Part A: Ratio of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)

    The LS means ratio of Day 10 over Day 1 were calculated from a mixed-model analysis of variance model.

    Time frame: Days 1 and 10 pre-dose and at multiple time points (up to 48 hours) post-dose

Secondary outcomes

  1. Part A: Total Clearance After Intravenous Administration (CL) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)

    Time frame: Days 1 and 10 pre-dose and at multiple time points (up to 48 hours) post-dose

  2. Part A: Volume of Distribution at Steady State After Intravenous Administration (Vss) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)

    Time frame: Days 1 and 10 pre-dose and at multiple time points (up to 48 hours) post-dose

  3. Part A: Terminal Disposition Phase Half-life (T1/2z) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)

    Time frame: Days 1 and 10 pre-dose and at multiple time points (up to 48 hours) post-dose

  4. Part B: Number of Participants With Best Overall Response as Per Investigator's Assessment

    Best overall response was defined as participants with best response among complete response (CR) or partial response (PR) or stable disease (SD), or progressive disease (PD). It was assessed by investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target and non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm). PR: at least 30 percent (%) decrease in sum of diameter of target lesions, taking as reference baseline sum of diameter. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum of diameter. PD: at least 20% increase in sum of diameter of target lesions, taking as reference, smallest sum on study.

    Time frame: Up to Cycle 17 (end of treatment) (Cycle length =21 days)

07

Results

Posted Apr 18, 2022

Participant flow

Participants took part in the study at 4 investigative sites in the United States from 13 August 2018 to 28 February 2021.

Part A
Participant flow — Part A
MilestonePart A: Pevonedistat 50 mg/m^2 + Rifampin 600 mgPart B: Pevonedistat 25 mg/m^2 + Docetaxel 75 mg/m^2Part B: Pevonedistat 20 mg/m^2 + Carboplatin AUC5+ Paclitaxel 175 mg/m^2
Started2000
Completed1700
Not completed300
Withdrew: Adverse event100
Withdrew: Symptomatic deterioration200
Part B
Participant flow — Part B
MilestonePart A: Pevonedistat 50 mg/m^2 + Rifampin 600 mgPart B: Pevonedistat 25 mg/m^2 + Docetaxel 75 mg/m^2Part B: Pevonedistat 20 mg/m^2 + Carboplatin AUC5+ Paclitaxel 175 mg/m^2
Started098
Completed098
Not completed000

Outcome measures

PrimaryPart A: Ratio of Maximum Observed Plasma Concentration (Cmax) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)

The Least square (LS) means ratio of Day 10 over Day 1 were calculated from a mixed-model analysis of variance model.

Time frame:
Days 1 and 10 pre-dose and at multiple time points (up to 48 hours) post-dose
Reported as:
Least squares mean · ratio
Part A: Ratio of Maximum Observed Plasma Concentration (Cmax) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)
ratioPart A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg
Part A: Ratio of Maximum Observed Plasma Concentration (Cmax) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)0.962 (0.792 to 1.168)
PrimaryPart A: Ratio of Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)

The LS means ratio of Day 10 over Day 1 were calculated from a mixed-model analysis of variance model.

Time frame:
Days 1 and 10 pre-dose and at multiple time points (up to 48 hours) post-dose
Reported as:
Least squares mean · ratio
Part A: Ratio of Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)
ratioPart A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg
Part A: Ratio of Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)0.785 (0.684 to 0.901)
PrimaryPart A: Ratio of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)

The LS means ratio of Day 10 over Day 1 were calculated from a mixed-model analysis of variance model.

Time frame:
Days 1 and 10 pre-dose and at multiple time points (up to 48 hours) post-dose
Reported as:
Least squares mean · ratio
Part A: Ratio of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)
ratioPart A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg
Part A: Ratio of Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)0.790 (0.692 to 0.902)
SecondaryPart A: Total Clearance After Intravenous Administration (CL) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)
Time frame:
Days 1 and 10 pre-dose and at multiple time points (up to 48 hours) post-dose
Reported as:
Mean · liter per hour (L/h)
Part A: Total Clearance After Intravenous Administration (CL) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)
liter per hour (L/h)Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg
Pevonedistat without rifampin (Day 1)35.22 ± 10.980
Pevonedistat with rifampin (Day 10)43.77 ± 12.604
SecondaryPart A: Volume of Distribution at Steady State After Intravenous Administration (Vss) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)
Time frame:
Days 1 and 10 pre-dose and at multiple time points (up to 48 hours) post-dose
Reported as:
Mean · liter
Part A: Volume of Distribution at Steady State After Intravenous Administration (Vss) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)
literPart A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg
Pevonedistat without rifampin (Day 1)312.82 ± 144.495
Pevonedistat with rifampin (Day 10)296.10 ± 136.297
SecondaryPart A: Terminal Disposition Phase Half-life (T1/2z) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)
Time frame:
Days 1 and 10 pre-dose and at multiple time points (up to 48 hours) post-dose
Reported as:
Mean · hour
Part A: Terminal Disposition Phase Half-life (T1/2z) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10)
hourPart A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg
Pevonedistat without rifampin (Day 1)7.442 ± 1.3846
Pevonedistat with rifampin (Day 10)5.708 ± 1.3665
SecondaryPart B: Number of Participants With Best Overall Response as Per Investigator's Assessment

Best overall response was defined as participants with best response among complete response (CR) or partial response (PR) or stable disease (SD), or progressive disease (PD). It was assessed by investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target and non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm). PR: at least 30 percent (%) decrease in sum of diameter of target lesions, taking as reference baseline sum of diameter. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum of diameter. PD: at least 20% increase in sum of diameter of target lesions, taking as reference, smallest sum on study.

Time frame:
Up to Cycle 17 (end of treatment) (Cycle length =21 days)
Reported as:
Count of participants · Participants
Part B: Number of Participants With Best Overall Response as Per Investigator's Assessment
ParticipantsPart B: Pevonedistat 25 mg/m^2 + Docetaxel 75 mg/m^2Part B: Pevonedistat 20 mg/m^2 + Carboplatin AUC5 + Paclitaxel 175 mg/m^2
CR00
PR21
SD23
PD23

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (From first dose of study drug up to Day 41 [Part A]; From first dose of study drug up to Cycle 17 Day 35 (Cycle length =21 days) [Part B]). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg1/20 (5%)3/20 (15%)11/20 (55%)
Part B: Pevonedistat 25 mg/m^2 + Docetaxel 75 mg/m^20/9 (0%)3/9 (33.3%)9/9 (100%)
Part B: Pevonedistat 20 mg/m^2 + Carboplatin AUC5+ Paclitaxel 175 mg/m^21/8 (12.5%)4/8 (50%)8/8 (100%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPart A: Pevonedistat 50 mg/m^2 + Rifampin 600 mgPart B: Pevonedistat 25 mg/m^2 + Docetaxel 75 mg/m^2Part B: Pevonedistat 20 mg/m^2 + Carboplatin AUC5+ Paclitaxel 175 mg/m^2
PneumoniaInfections and infestations1/202/90/8
Rectal haemorrhageGastrointestinal disorders0/200/91/8
NauseaGastrointestinal disorders0/200/91/8
DyspnoeaRespiratory, thoracic and mediastinal disorders0/200/91/8
HypoxiaRespiratory, thoracic and mediastinal disorders0/200/91/8
Enterocolitis infectiousInfections and infestations0/201/90/8
SepsisInfections and infestations0/201/90/8
Febrile neutropeniaBlood and lymphatic system disorders0/201/90/8
HypersensitivityImmune system disorders1/200/90/8
Septic shockInfections and infestations1/200/90/8
Most frequent other events
Showing 10 of 84
Most frequent other events
EventPart A: Pevonedistat 50 mg/m^2 + Rifampin 600 mgPart B: Pevonedistat 25 mg/m^2 + Docetaxel 75 mg/m^2Part B: Pevonedistat 20 mg/m^2 + Carboplatin AUC5+ Paclitaxel 175 mg/m^2
FatigueGeneral disorders3/205/92/8
Peripheral sensory neuropathyNervous system disorders0/202/94/8
Urinary tract infectionInfections and infestations0/204/91/8
AnaemiaBlood and lymphatic system disorders0/200/93/8
Abdominal painGastrointestinal disorders0/201/93/8
ConstipationGastrointestinal disorders0/200/93/8
Pain in extremityMusculoskeletal and connective tissue disorders0/200/93/8
DiarrhoeaGastrointestinal disorders6/203/92/8
PyrexiaGeneral disorders2/203/90/8
NauseaGastrointestinal disorders2/202/92/8

Baseline characteristics

The safety analysis set for Part A was defined as all enrolled participants who received at least a single pevonedistat dose during Part A.

Age, Continuous
Age, Continuous(years)Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg
Mean64.9 ± 8.70
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg
Female10
Male10
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg
Hispanic or Latino0
Not Hispanic or Latino20
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American4
White15
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg
United States20
Height
Height(centimeter (cm))Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg
Mean171.91 ± 10.235
Weight
Weight(kilogram (kg))Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg
Mean87.13 ± 22.667
Body Surface Area (BSA)
Body Surface Area (BSA)(square meter (m^2))Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg
Mean2.03 ± 0.307
08

Study locations

4 sites
  • Emory University
    Atlanta, Georgia 30308, United States
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
    Chicago, Illinois 60611, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201-2013, United States
  • Greenville Health System - Institute for Translational Oncology Research
    Greenville, South Carolina 29605, United States
09

References and documents

Publications

  • Zhou X, Vaishampayan U, Mahalingam D, Harvey RD, Chung KY, Sedarati F, Dong C, Faller DV, Venkatakrishnan K, Gupta N. Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors. Invest New Drugs. 2022 Oct;40(5):1042-1050. doi: 10.1007/s10637-022-01286-8. Epub 2022 Aug 6. PubMed 35932388 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in May 2019, 8 months.

Results were first posted in Apr 2022, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2018
First posted
Apr 3, 2018
StartActual
Aug 13, 2018
Primary completionActual
May 10, 2019
CompletionActual
Feb 28, 2021
Results first posted
Apr 18, 2022
Last update
Apr 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03486314
Responsible party
Sponsor
First posted
Apr 3, 2018
Start date
Aug 13, 2018
Primary completion
May 10, 2019
Completion
Feb 28, 2021
Results posted
Apr 18, 2022
Last update
Apr 18, 2022

Study contacts

Medical Director
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rifampin

Start the discussion